AtriCure Appoints Scott Drake to Its Board of Directors

WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (NASDAQ: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that Scott Drake, Chief Executive Officer of the Spectranetics Corporation, has been elected as Director. Donald C. Harrison, MD, one of the founders of AtriCure, has also informed the Board of Directors of his plans to retire at the 2013 Annual Meeting in May 2014, following an orderly transition and after almost 20 years of service with the company.